Baraliakos, X., Braun, J., Laurent, D., Baeten, D., van der Heijde, D., Sieper, J., . . . Hueber, W. (2013). Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis.
Chicago-čujuhus (17. p.)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
MLA-čujuhus (9. p.)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.